Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NDRA vs DARE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NDRA Captures Overall Composite Edge (44.7 HOLD vs 45.7 HOLD), While DARE Leads 3–1 on Growth & Valuation Pillars
NDRA Overall Winner
6-Pillar Tally: NDRA 1 – 3 DARE (2 Tie)
Matrix Metrics: NDRA 4 – 4 DARE
As of Nov 16, 2026, ENDRA Life Sciences Inc. (NDRA) captures the overall head-to-head institutional edge over Dare Bioscience, Inc. (DARE) on higher Unified Composite conviction (44.7/100 HOLD vs. 45.7/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality), while DARE wins 3–1 across the 6-pillar growth and valuation breakdown. NDRA trades at $4.42 (N/M Forward P/E, 0.0% operating margin) versus DARE at $0.58 (1.3x Forward P/E, -813.4% operating margin).
- Composite vs. Pillar Nuance: While DARE currently prints a higher short-term Unified Composite Score (45.7/100 HOLD vs. NDRA 44.7/100 HOLD), NDRA captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -813.4% operating margin) and revenue trajectory (+0.0% vs. +499.6% YoY).
- Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile DARE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About NDRA vs DARE
NDRA
Head-to-Head Winner
ENDRA Life Sciences Inc. Common Stock
$4.42
+0.23% 1D
Market Cap
$6.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.71β · 48% Vol
Unified Composite Score
44.7
HOLD
Tech 35.0
Fund 46.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
DARE
Dare Bioscience, Inc. Common Stock
$0.58
-11.13% 1D
Market Cap
$12.9M
TTM Revenue
$1.4M
Forward P/E
1.3x
Beta / 30D Vol
1.40β · 62% Vol
Unified Composite Score
45.7
HOLD
Tech 33.0
Fund 52.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (NDRA 1 – 3 DARE)
1. Valuation Multiples
DARE
Forward P/E
N/M
1.3x
Trailing P/E
N/M
1.3x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
1.0x
2. Growth & Scale
DARE
Revenue Growth (YoY)
+0.0%
+499.6%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$1.4M
Market Cap
$6.6M
$12.9M
3. Profitability & Quality
NDRA
Gross Margin
N/A
N/A
Operating Margin
0.0%
-813.4%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-152.0%
-2543.1%
4. Balance Sheet & Cash Flow
DARE
Cash Generation (TTM)
-$8.0M
-$12M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$104,744 Net Debt (0.26x D/E)
$12M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Diagnostics & Research Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: NDRA (4) vs DARE (4)| Institutional Metric | NDRA | DARE | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $6.6M | $12.9M | Tie | |
| Trailing P/E Ratio | N/M | 1.3x | DARE | |
| Forward P/E Ratio | N/M | 1.3x | DARE | |
| Revenue Growth (YoY) | +0.0% | +499.6% | DARE | |
| Operating Margin (TTM) | 0.0% | -813.4% | NDRA | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -152.0% | -2543.1% | NDRA | |
| 52-Week Range Position | 37% ($3–$7) | 0% ($1–$4) | NDRA | |
| Beta / 30D Volatility | 0.71β · 48% Vol | 1.40β · 62% Vol | NDRA | |
| Unified Institutional Score | 44.7 / 100 (HOLD) | 45.7 / 100 (HOLD) | DARE | |
| Trailing 12M Revenue (USD) | N/A | $1.4M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 1.0x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$8.0M ($104,744 Net Debt (0.26x D/E)) | -$12M ($12M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
NDRA +12.63 pp
3M Horizon
NDRA +21.95 pp
6M Horizon
NDRA +54.01 pp
1Y Horizon
NDRA +36.37 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | NDRA Revenue | DARE Revenue | NDRA Op. Margin | DARE Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2014 | N/A | $0M | N/A | -29177.5% | DARE |
| FY2016 | $0M | $0M | -347.5% | -82.3% | DARE |
| FY2017 | $0M | N/A | -1315.6% | N/A | NDRA |
| FY2018 | $0M | N/A | -146080.5% | N/A | NDRA |
| FY2022 | N/A | $10M | N/A | -313.9% | DARE |
| FY2023 | N/A | $0M | N/A | -1101.9% | DARE |
| FY2024 | N/A | $0M | N/A | -239692.2% | DARE |
| FY2025 | N/A | $0M | N/A | -1315.5% | DARE |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
NDRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
DARE
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact DARE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
NDRA Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
DARE Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ NDRA vs DARE Key Questions & Quantitative Answers
As of Nov 16, 2026, ENDRA Life Sciences Inc. (NDRA) captures the overall head-to-head institutional edge over Dare Bioscience, Inc. (DARE) on higher Unified Composite conviction (44.7/100 HOLD vs. 45.7/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality), while DARE wins 3–1 across the 6-pillar growth and valuation breakdown. NDRA trades at $4.42 (N/M Forward P/E, 0.0% operating margin) versus DARE at $0.58 (1.3x Forward P/E, -813.4% operating margin). Composite vs. Pillar Nuance: While DARE currently prints a higher short-term Unified Composite Score (45.7/100 HOLD vs. NDRA 44.7/100 HOLD), NDRA captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -813.4% operating margin) and revenue trajectory (+0.0% vs. +499.6% YoY). Technical & Structure Timing Caution: NDRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7); meanwhile DARE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DARE leads the Growth & Scale pillar: NDRA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DARE at +499.6% YoY revenue growth and +0.0% YoY earnings growth on $1.4M TTM revenue (N/A gross margin, -813.4% operating margin). Across the 8-period historical trajectory (FY2014 to FY2025), NDRA cumulative revenue shifted N/A while DARE shifted N/A. In operating R&D and SG&A reinvestment, NDRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DARE.
DARE screens cheaper on headline valuation multiples. NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DARE trades at 1.3x Forward P/E, 1.3x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NDRA (-152.0% ROE) versus DARE (-2543.1% ROE) capital efficiency.
In options market volatility and institutional positioning, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk). By comparison, DARE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.40β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
DARE vs NDRA · Reverse Pair
DARE vs VTVT
· Sector Peer
DARE vs ACHV
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal